Paul N. Hopkins
Brigham and Women's Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Paul N. Hopkins.
Hypertension | 1992
Robert G. Dluhy; Richard P. Lifton; Thomas J. Moore; Ray E. Gleason; Roger R. Williams; Steven C. Hunt; Paul N. Hopkins; Norman K. Hollenberg
Non-modulation is a trait characterized by abnormal angiotensin-mediated control of aldosterone release and the renal blood supply. To determine whether non-modulation defines a specific subgroup of the hypertensive population and its utility as an intermediate phenotype, we have studied the distribution of this quantitative trait, whether its features are reproducible on repeated testing, and whether there is concordance of its multiple features. Essential hypertensive patients (224) and normotensive subjects (119) received an infusion of angiotensin II (Ang II) at 3 ng.kg-1.min-1 for 30-45 minutes. p-Aminohippurate (PAH) clearance was assessed as an index of renal plasma flow while the subjects were on a 200 meq sodium diet; plasma aldosterone levels were measured while the subjects were on a 10 meq sodium diet. In 54 subjects, diuretic-induced volume depletion superimposed on a low salt diet was substituted for the Ang II infusion. The results of each study were submitted to maximum likelihood analysis to assess bimodality. In response to both diuretic-induced volume depletion (p < 0.000023) and Ang II infusion (p < 0.0009), aldosterone responses were bimodally distributed in the essential hypertensive but not in the normotensive subjects, suggesting that this trait identifies a discrete subgroup. In the 59 subjects who had both an adrenal and renal study, 50 (85%) were concordant. Finally, in 27 subjects studied two to six times over a span of 1-60 months, the intraclass correlations of the adrenal, PAH, or both responses were highly significant (p values between 0.001 and 0.00007), indicating high reproducibility of results on repeated testing.(ABSTRACT TRUNCATED AT 250 WORDS)
Hypertension | 1989
Richard P. Lifton; Paul N. Hopkins; Roger R. Williams; Norman K. Hollenberg; Robert G. Dluhy
We have previously described a subset of subjects with essential hypertension who fail to appropriately modulate renal vascular and adrenal reactivity with changes in dietary sodium and in response to infused angiotensin II (Ang II). In this paper, we studied these responses in 13 unselected hypertensive subjects in whom the family history of hypertension had been carefully detailed. Nine of these 13 subjects had a positive family history (FH+) for hypertension and had significantly smaller decrements in renal blood flow with Ang II infusion than the four subjects who had a negative family history (FH−) (−84±16 ml/min/1.73 m+ for FH+ vs. −149 ml/min/1.73 m2 for FH−, p = 0.024). These FH+ subjects also showed smaller increases in renal blood flow with increases in dietary sodium than FH− subjects (7±10 ml/min/1.73 m2 vs. 72±-24 ml/min/1.73 m+, respectively; p = 0.014). When classified as modulators or non-modulators by previously established criteria, all seven non-modulators were FH+, and seven of nine FH+ subjects were non-modulators. This association between non-modulation and family history of hypertension is significant (p = 0.021). To further clarify the association between non-modulation and family history of hypertension, we have studied the renal blood flow response to Ang II in 31 hypertensive siblings from 14 sibships. Twenty-five of these 31 subjects (81%) behaved as non-modulators (p = 0.008 compared with expected value in an unselected hypertensive population). Additionally, strong concordance of non-modulation between sibling pairs was observed (p = 0.004). These findings indicate that a high proportion of FH+ subjects are non-modulators and that nonmodulation shows familial aggregation. These observations together strongly suggest that non-modulation is a heritable trait. Furthermore, the high prevalence of non-modulation in FH+ subjects further suggests that this trait may be one of the most important heritable factors in essential hypertension.
American Journal of Hypertension | 2002
Nadarajah Srikumar; Nancy J. Brown; Paul N. Hopkins; Xavier Jeunemaitre; Steven C. Hunt; Douglas E. Vaughan
BACKGROUNDnAlthough the renin-angiotensin system and insulin resistance (IR) have been identified as major regulators of plasminogen activator inhibitor type-1 (PAI-1), their roles in hypertensive subjects is not clearly defined.nnnMETHODSnWe examined the effect of dietary salt restriction on PAI-1 levels in 239 hypertensive subjects from three centers. Subjects were placed on a 200 and 10 mmol/day sodium diets for 1-week periods. Plasma renin activity (PRA) and PAI-1 levels were measured on the last day of both diets and fasting insulin, glucose, and aldosterone (ALDO) levels, only on the low salt diet.nnnRESULTSnSodium restriction increased PAI-1 levels from 32.1 +/- 2.5 ng/mL to 39.8 +/- 3.2 ng/mL (P = .009). There was a strong positive correlation between PAI-1 levels and PRA (r = 0.228, P = .0004), IR (r = 0.222, P = .001), triglycerides (r = 0.275, P < .001), and ALDO (P = .018 for linear trend). The patients were divided into low renin (low IR and ALDO levels), nonmodulators (normal PRA, high IR, and low ALDO levels), and modulators (normal PRA, intermediate IR, and normal ALDO levels) groups to assess the relative contribution of each factor to PAI-1 levels. Modulators had significantly (P = .019) higher PAI-1 levels compared to the low renin and nonmodulators who had similar PAI-1 levels.nnnCONCLUSIONSnPlasma renin activity, IR, and ALDO all correlate with PAI-1 levels in the hypertensive subjects. However, the data suggest that ALDO may be an important factor contributing to the variability of PAI-1 levels in individual hypertensive subjects.
Archive | 1998
Roger R. Williams; Steven C. Hunt; Paul N. Hopkins; Lily L. Wu; Jean-Marc Lalouel
Applying our growing understanding of genes that promote hypertension in humans should lead to more accurate diagnoses and more effective treatment. Furthermore in some cases it can already help us prevent avoidable early deaths. This discussion covers several dominant endocrine syndromes causing severe hypertension and preventable early deaths. We also discuss a very common genetic variant at the angiotensinogen locus that seems to be a gene for “salt sensitive hypertension.”
Kidney International | 2004
Todd S. Perlstein; Olga Gumieniak; Paul N. Hopkins; Laine J. Murphey; Nancy J. Brown; Norman K. Hollenberg; Naomi D.L. Fisher
Archive | 2009
Roger R. Williams; Paul N. Hopkins; Lily L. Wu; Steven C. Hunt
American Journal of Hypertension | 2000
N.D.L. Fisher; Steven C. Hunt; Shelley Hurwitz; X. Jeunemaitre; Paul N. Hopkins; Norman K. Hollenberg
Archive | 2012
Brian H. Shirts; Steven C. Hunt; Paul N. Hopkins
Archive | 2007
Rhonda Bentley-Lewis; Gail K. Adler; Todd S. Perlstein; Ellen W. Seely; Paul N. Hopkins; Rajesh Garg
Journal of Investigative Medicine | 2004
Olga Gumieniak; Todd S. Perlstein; Paul N. Hopkins; Nancy J. Brown; X. Jeunemaitre